目的 系统性评价宁泌泰胶囊治疗慢性前列腺炎的经济性。方法 检索中国知网、万方、维普以及PubMed数据库，收集从2000年1月至2020年9月发表的关于宁泌泰胶囊及其同类产品治疗慢性前列腺炎的临床试验，治疗周期为4周。纳入分析的化学药包括α-受体阻滞剂和抗生素，中成药品种包括癃清片、三金片、双石通淋胶囊、前列舒通胶囊、前列倍喜胶囊。统计不同药品纳入文献的治疗总有效率，核算总治疗成本，计算成本-效果比和增量成本-效果比（incremental cost-effectiveness ratio，ICER）。结果 共纳入83项研究，6467例患者。比较分析单用α-受体阻滞剂（坦索罗辛）、抗生素（左氧氟沙星）、宁泌泰胶囊以及宁泌泰胶囊与上述药物联合使用治疗慢性前列腺炎时的经济性，结果显示宁泌泰胶囊联合坦索罗辛成本效果比最低，且相比单用坦索罗辛，临床有效率每提高1个单位，成本仅增加8.2元。进一步比较分析宁泌泰胶囊或其同类中成药联合化学药（包括α-受体阻滞剂、抗生素或二者联用）治疗慢性前列腺炎的经济性，结果显示治疗总成本最低的为三金片联合化学药或宁泌泰胶囊联合化学药，相比单用化学药，两者总成本均略有降低，而疗效提升明显，ICER均为负值，但三金片临床主要用于尿路感染的治疗。此外，癃清片、双石通淋胶囊、前列舒通胶囊、前列倍喜胶囊分别联合化学药总成本均出现不同程度增加，但疗效与宁泌泰联合用药相当。结论 宁泌泰胶囊缓解疼痛或不适、抑制细菌生物膜的特点使其在临床使用时可与化学药的疗效形成优势互补，并且不会增加总成本，使医保患者在获得最佳治疗体验的同时控制医疗总成本的上涨，减轻医保资金压力和患者负担。

Objective To systematically evaluate the economics of Ningmitai Capsules (宁泌泰胶囊) in the treatment of chronic prostatitis. Methods Clinical trials on Ningmitai Capsules and similar products in the treatment of chronic prostatitis published from January, 2000 to September, 2020 from CNKI, Wanfang, VP and PubMed databases. The treatment period was four weeks. The chemical drugs included in the analysis and comparison included α-receptor blockers and antibiotics. The varieties of proprietary Chinese medicines included Longqing Tablets (癃清片), Sanjin Tablets (三金片), Shuangshi Tonglin Capsules (双石通淋胶囊), Qianlie Shutong Capsules (前列舒通胶囊), Qianlie Beixi Capsules (前列倍喜胶囊). The total effective rate of different drugs included in the literature was counted, the total treatment cost, the cost-effectiveness ratio and the incremental cost-effectiveness ratio (ICER) were calculated. Results A total of 83 studies with 6467 cases were included. The economics of single-use α-receptor blockers (tamsulosin), antibiotics (levofloxacin), Ningmitai Capsules and Ningmitai Capsules combination with the above drugs in the treatment of chronic prostatitis were compared and analyzed, the results showed that Ningmitai Capsules combined with tamsulosin had the lowest cost-effectiveness ratio, and compared with tamsulosin alone, the clinical effective rate increased by one unit, and the cost only increased by 8.2 yuan. The economics of Ningmitai Capsules or its similar Chinese patent medicine combined with chemical drugs (including α-receptor blockers, antibiotics or a combination of the two) in the treatment of chronic prostatitis were further compared and analyzed, the results showed that the total cost of Sanjin Tablets combined with chemical drugs or Ningmitai Capsules combined with chemical drugs was the lowest; Compared with the single-use chemical drugs, the total cost of both drugs was slightly reduced, the efficacy was significantly improved, and ICER was negative, but Sanjin Tablets are mainly used in the treatment of urinary tract infection. In addition, the total cost of Longqing Tablets, Shuangshi Tonglin Capsules, Qianlie Shutong Capsules, and Qianlie Beixi Capsules respectively combined with chemical drugs were increased in different degrees, but the efficacy was comparable to that of Ningmitai Capsules combination. Conclusions The characteristics of relieving pain or discomfort and inhibiting bacterial biofilm of Ningmitai Capsules make it complementary to the efficacy of chemical drugs in clinical use, and will not increase the total cost, so that medical insurance patients can get the best treatment experience. At the same time, the total cost of medical care should be controlled to reduce the pressure on medical insurance funds and the burden on patients.

R285.64